Patents by Inventor Emil D. Kakkis

Emil D. Kakkis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Induction of antigen specific immunologic tolerance
    Publication number: 20030211113
    Abstract: Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 13, 2003
    Inventors: Emil D. Kakkis, Merry Passage, Thomas Lester, Rebecca Q Yang, Christopher Tanaka
  • Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
    Patent number: 6585971
    Abstract: The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: July 1, 2003
    Assignee: Harbor-UCLA Research and Education Institute
    Inventor: Emil D. Kakkis
  • Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
    Patent number: 6569661
    Abstract: The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: May 27, 2003
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Minmin Qin, Wai-Pan Chan, Lin Chen, Paul A. Fitzpatrick, John M. Hendstrand, Dan J. Wendt, Gary N. Zecherle, Christopher M. Starr, Emil D. Kakkis
  • Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
    Publication number: 20030013179
    Abstract: The present invention provides a recombinant &agr;-L-iduronidase and biologically active fragments and mutants thereof, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including—&agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
    Type: Application
    Filed: July 25, 2002
    Publication date: January 16, 2003
    Inventors: Emil D. Kakkis, Becky Tanamachi
  • Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase
    Publication number: 20020164758
    Abstract: The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant &agr;-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1) by administering said formulation.
    Type: Application
    Filed: November 13, 2001
    Publication date: November 7, 2002
    Inventor: Emil D. Kakkis
  • Methods for producing and purifying recombinant alpha-L-iduronidase
    Publication number: 20020146802
    Abstract: The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and muteins thereof with a purity greater than 99%. The present invention further provides large-scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme thereof.
    Type: Application
    Filed: November 13, 2001
    Publication date: October 10, 2002
    Inventors: Minmin Qin, Wai-Pan Chan, Lin Chen, Paul A. Fitzpatrick, John M. Henstrand, Dan J. Wendt, Gary N. Zecherle, Christopher M. Starr, Emil D. Kakkis
  • Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
    Patent number: 6426208
    Abstract: The present invention provides a recombinant &agr;-L-iduronidase and biologically active fragments and mutants thereof, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including- &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: July 30, 2002
    Assignee: Harbor-UCLA Research and Education Institute
    Inventors: Emil D. Kakkis, Becky Tanamachi